Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than…
Browsing: ipilimumab
The Oncology Journal Club Episode 18
Find out why coffee is so good for you and hear the team sing Baby…
Prostate cancer: immunotherapy offers hope
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant…
Immunotherapy offers hope for prostate cancer treatment
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant…
Combination immunotherapy benefits subset of patients with advanced prostate cancer
Results from a Phase II trial led by researchers at The University of Texas MD…
IASLC WCLC 2020: CheckMate-743 shows that dual immunotherapy, nivolumab plus ipilimumab improves overall survival for patients with previously untreated mesothelioma
The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients…
ASCO 2020: Trial confirms durable and long-term survival benefit for nivolumab plus ipilimumab over chemotherapy in metastatic first-line non-small cell lung cancer patients
Today three-year follow-up results from Part 1 of the Phase 3 CheckMate -227 trial have…
Immunotherapy effective in metastatic prostate cancers with specific markers of immune activation
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of…
FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma
The Food and Drug Administration (FDA) granted accelerated approval to the combination of nivolumab and…
ASCO GU 2020: Nivolumab plus ipilimumab benefit for advanced kidney cancer
Updated results have been released from the Phase 3 CheckMate -214 study evaluating the combination…